SAN CARLOS, CALIFORNIA, April 29, 2026
BeOne Medicines has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). The designation underscores the potential of this novel combination regimen to significantly improve patient outcomes in a disease with historically poor prognosis. The FDA also granted Breakthrough Therapy Designation for the ZIIHERA-based regimen, further accelerating its regulatory pathway and highlighting its clinical importance in oncology innovation.
Phase 3 HERIZON-GEA-01 Data Shows Unprecedented Survival
The sBLA submission is supported by results from the global Phase 3 HERIZON-GEA-01 trial, a large-scale study involving 914 patients across more than 30 countries, evaluating the efficacy of TEVIMBRA in combination with ZIIHERA and chemotherapy. The trial demonstrated a statistically significant improvement in overall survival (OS), with patients receiving the TEVIMBRA-containing regimen achieving a median OS of 26.4 months, compared to 19.2 months in the control arm, representing a major advancement in first-line treatment for HER2-positive GEA.
Additionally, the study reported a median progression-free survival (PFS) of 12.4 months, significantly higher than the 8.1 months observed in the standard-of-care group. These outcomes were consistent across patient subgroups, regardless of PD-L1 expression status, reinforcing the therapy’s broad clinical applicability.
Innovative Dual-Antibody Strategy Enhances Treatment Outcomes
Advertisement
The combination of TEVIMBRA, a PD-1 immune checkpoint inhibitor, with ZIIHERA, a bispecific HER2-targeted antibody, represents a novel dual-targeted therapeutic approach in oncology. TEVIMBRA enhances the immune system’s ability to detect and attack cancer cells, while ZIIHERA binds to two distinct HER2 receptor sites, triggering multiple anti-tumor mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated responses.
This synergistic mechanism is designed to maximize tumor cell destruction while maintaining a manageable safety profile, with clinical data showing no new safety concerns beyond known effects of the individual components. The integration of immunotherapy with targeted biologics reflects a growing trend in precision oncology, where combination regimens are increasingly used to improve efficacy in complex cancers.
Accelerating Global Regulatory Pathways and Patient Access
BeOne Medicines plans to leverage the FDA’s Project Orbis initiative, enabling collaborative international regulatory review to accelerate approvals across multiple global markets. This strategy aims to reduce time-to-market and expand patient access to innovative therapies in regions where treatment options remain limited.
From a GxP perspective, the HERIZON-GEA-01 trial was conducted in accordance with Good Clinical Practice (GCP) standards, ensuring robust data integrity, patient safety, and regulatory compliance. The Priority Review designation further reflects the FDA’s recognition of the therapy’s potential to address a significant unmet medical need, particularly in HER2-positive GEA, which affects approximately 20% of patients with gastroesophageal cancers and is associated with high morbidity and low survival rates. As regulatory review progresses, the TEVIMBRA-based combination has the potential to redefine first-line treatment standards, offering a new, highly effective therapeutic option for patients worldwide.
Source: BeOne Medicines press release
